Atara Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
ATRA$8.18+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $25,841 | $92,942 |
| Short-term investments | 25,884 | 149,877 |
| Restricted cash | 146 | 146 |
| Accounts receivable | 34,108 | 40,221 |
| Inventories | 9,706 | 1,586 |
| Other current assets | 6,184 | 10,308 |
| Total current assets | 101,869 | 295,080 |
| Property and equipment, net | 3,856 | 6,300 |
| Operating lease assets | 54,935 | 68,022 |
| Other assets | 4,844 | 7,018 |
| Total assets | $165,504 | $376,420 |
| Liabilities and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $3,684 | $6,871 |
| Accrued compensation | 11,519 | 17,659 |
| Accrued research and development expenses | 17,364 | 24,992 |
| Deferred revenue | 77,833 | 8,000 |
| Other current liabilities | 31,826 | 21,394 |
| Total current liabilities | 142,226 | 78,916 |
| Deferred revenue – long-term | 37,562 | 77,000 |
| Operating lease liabilities – long-term | 45,693 | 58,064 |
| Liability related to the sale of future revenues – long-term | 34,623 | 30,236 |
| Other long-term liabilities | 4,631 | 5,564 |
| Total liabilities | 264,735 | 249,780 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity (deficit): | ||
| Common stock—$0.0001 par value, 500,000 shares authorized as of December 31, 2023 and 2022, respectively; 106,447 and 95,927 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 11 | 10 |
| Additional paid-in capital | 1,870,112 | 1,821,721 |
| Accumulated other comprehensive (loss) income | (204) | (2,067) |
| Accumulated deficit | (1,969,150) | (1,693,024) |
| Total stockholders’ equity (deficit) | (99,231) | 126,640 |
| Total liabilities and stockholders’ equity (deficit) | $165,504 | $376,420 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.